Samlyn Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-420,355
| Closed | -$108M | – | 86 |
|
|
2023
Q3 | $108M | Buy |
420,355
+25,083
| +6% | +$6.71M | 1.77% | 17 |
|
|
2023
Q2 | $113M | Sell |
395,272
-3,818
| -1% | -$1.14M | 1.91% | 12 |
|
|
2023
Q1 | $111M | Buy |
399,090
+132,127
| +49% | +$36.6M | 2.01% | 17 |
|
|
2022
Q4 | $73.9M | Buy |
266,963
+130,558
| +96% | +$36.9M | 1.45% | 22 |
|
|
2022
Q3 | $36.4M | Sell |
136,405
-6,181
| -4% | -$1.31M | 0.68% | 45 |
|
|
2022
Q2 | $29.1M | Sell |
142,586
-36,426
| -20% | -$7.45M | 0.58% | 44 |
|
|
2022
Q1 | $37.7M | Sell |
179,012
-483
| -0.3% | -$105K | 0.54% | 53 |
|
|
2021
Q4 | $43.1M | Buy |
179,495
+57,160
| +47% | +$14.7M | 0.59% | 50 |
|
|
2021
Q3 | $34.6M | Sell |
122,335
-253,896
| -67% | -$83.2M | 0.46% | 61 |
|
|
2021
Q2 | $130M | Buy |
+376,231
| New | +$114M | 1.91% | 15 |
|
|
2020
Q4 | – | Sell |
-107,626
| Closed | -$30.5M | – | 162 |
|
|
2020
Q3 | $30.5M | Sell |
107,626
-11,661
| -10% | -$3.25M | 0.55% | 57 |
|
|
2020
Q2 | $31.9M | Buy |
119,287
+16,440
| +16% | +$4.94M | 0.59% | 53 |
|
|
2020
Q1 | $32.5M | Sell |
102,847
-14,231
| -12% | -$4.32M | 0.82% | 40 |
|
|
2019
Q4 | $34.7M | Buy |
+117,078
| New | +$32.5M | 0.73% | 49 |
|
|
2019
Q1 | – | Sell |
-128,645
| Closed | -$40.5M | – | 100 |
|
|
2018
Q4 | $38.7M | Sell |
128,645
-55,606
| -30% | -$17.7M | 0.92% | 38 |
|
|
2018
Q3 | $65.1M | Buy |
184,251
+103,659
| +129% | +$35.7M | 1.47% | 20 |
|
|
2018
Q2 | $23.4M | Buy |
80,592
+820
| +1% | +$231K | 0.55% | 69 |
|
|
2018
Q1 | $21.8M | Sell |
79,772
-254,342
| -76% | -$79M | 0.48% | 74 |
|
|
2017
Q4 | $106M | Sell |
334,114
-126,529
| -27% | -$40.6M | 2.44% | 4 |
|
|
2017
Q3 | $144M | Sell |
460,643
-249,857
| -35% | -$74M | 3.64% | 3 |
|
|
2017
Q2 | $193M | Buy |
710,500
+278,400
| +64% | +$73.6M | 4.71% | 1 |
|
|
2017
Q1 | $118M | Buy |
432,100
+275,500
| +176% | +$77.9M | 2.74% | 2 |
|
|
2016
Q4 | $44.4M | Sell |
156,600
-224,902
| -59% | -$66.7M | 1.01% | 41 |
|
|
2016
Q3 | $119M | Sell |
381,502
-149,425
| -28% | -$44.3M | 2.84% | 4 |
|
|
2016
Q2 | $128M | Buy |
530,927
+233,420
| +78% | +$61.5M | 3.07% | 5 |
|
|
2016
Q1 | $77.4M | Buy |
297,507
+55,507
| +23% | +$14.7M | 1.66% | 21 |
|
|
2015
Q4 | $74.1M | Buy |
242,000
+58,400
| +32% | +$16.8M | 1.54% | 24 |
|
|
2015
Q3 | $53.6M | Buy |
+183,600
| New | +$60.6M | 0.98% | 44 |
|
|
2013
Q4 | – | Sell |
-89,596
| Closed | -$21.6M | – | 94 |
|
|
2013
Q3 | $21.6M | Buy |
89,596
+3,096
| +4% | +$693K | 0.6% | 68 |
|
|
2013
Q2 | $18.6M | Buy |
+86,500
| New | +$18.5M | 0.54% | 70 |
|
Other funds holding BIIB
Samlyn Capital's BIIB Position: Q4 2023 in Review
Samlyn Capital sold out of Biogen (BIIB) in Q4 2023, closing a stake of 420,355 shares — an estimated $108M sold.
Samlyn Capital first reported a position in BIIB in Q2 2013 and held it in 30 quarters. The position peaked at $193M in Q2 2017. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.
- Samlyn Capital reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
- Samlyn Capital sold 420,355 Biogen shares in Q4 2023, an estimated $108M.
- Samlyn Capital first reported a position in Biogen in Q2 2013 and held it in 30 quarters.
- Samlyn Capital's Biogen position peaked at $193M in Q2 2017.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.
Based on Samlyn Capital's 13F filing for Q4 2023, filed 14 Feb 2024.